rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GTCB 2007 ******

2.783 Posts
Pagina: «« 1 ... 65 66 67 68 69 ... 140 »» | Laatste | Omlaag ↓
  6. [verwijderd] 17 april 2007 17:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    GTC is presenting at the Rodman conference in Monte Carlo, May 14-15:

    http://www.rodmanandrenshaw.com/Conferences.asp?CID=conf20&ACT=presenters&BGCOLOR=wht

    BIO Dree
  7. [verwijderd] 17 april 2007 17:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    We know the potential for sales of Atryn. What will push our little gem up?
    Is when negotiations are finished and sales start: 2nd quarter.

    Voor de vakantie in GTCB !
    BIO Dree
  8. [verwijderd] 17 april 2007 19:50

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    FOR IMMEDIATE RELEASE
    http://www.merrimackpharma.com/newsEvents/2007/RA_Initiation_17April07_FINAL.pdf


    Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis.

    CAMBRIDGE, Mass., April 17, 2007 – Merrimack

    Pharmaceuticals, Inc. today announced the
    initiation of a Phase 2 study to evaluate the safety and efficacy of its immunomodulator, MM-093,
    in patients suffering from rheumatoid arthritis (RA). MM-093, Merrimack's lead product, is a
    recombinant version of human alpha-fetoprotein (AFP).
    The randomized, double-blind, placebo-controlled, Phase 2 study is being conducted at 15
    centers throughout the United States. The objective of this study is to examine the safety and
    efficacy of MM-093 in approximately 90-100 patients with moderate to severe, active RA despite
    stable doses of methotrexate. Each patient will receive 60mg of MM-093 per week or placebo for
    12 weeks and will then be followed for an additional 4 weeks. In addition to evaluating the safety
    of MM-093, patients will be assessed for changes in the signs and symptoms of their disease
    using standard clinical outcome measurements for RA, such as ACR20 and DAS28 scores.
    “MM-093 has been well-tolerated in studies to date and we believe its unique profile will
    differentiate it from other therapies and allow it to make a significant difference in the highly
    competitive RA market,” said Robert Mulroy, President & CEO of Merrimack. “Despite the
    advances that have been made in treating the signs and symptoms of RA, there remains a
    significant need for safer, more effective therapies.”
    This study follows an exploratory Phase 2, dose-ranging study of MM-093 in patients with RA
    completed in 2006. Merrimack is presenting results from that trial at the European League
    Against Rheumatism (EULAR) conference in Barcelona this spring. MM-093 has also completed
    both a Phase 1 study in healthy volunteers and a pilot study in RA patients that demonstrated it
    was well tolerated and bioactive in addressing the signs and symptoms of RA.
    Merrimack controls a strong intellectual property estate around MM-093 including 14 issued
    patents and a number of pending applications, both in the U.S. and internationally, which cover
    composition of matter, production methods and therapeutic uses of the drug.
    Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and
    development of novel treatments for diseases in the areas of autoimmune disease and cancer. Its
    lead compound, MM-093, is currently in clinical development to treat patients with rheumatoid
    arthritis, psoriasis or with autoimmune uveitis. MM-093 is an investigational drug and has not
    been approved by the U.S. Food and Drug Administration or any international regulatory agency.
    The company's proprietary Network Biology discovery platform, developed with the help of
    leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks
    as a basis for improved validation, lead identification and speed in the development of innovative,
    effective and safe therapeutics. Merrimack is a privately held company based in Cambridge,
    Massachusetts. For additional information, please visit www.merrimackpharma.com.
    Contact: Kathleen Petrozzelli, Manager, Corporate Communications, 617-441-1043

    http://www.merrimackpharma.com/

  9. [verwijderd] 17 april 2007 20:01

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Merrimack is presenting results from that trial at the European League Against Rheumatism (EULAR)
    conference in Barcelona this spring.
    13-16 June 2007
    CCIB Congress Centre
    Barcelona-Spain

  15. [verwijderd] 18 april 2007 11:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    javascript:qm_showFilingOutline_7260('http://quotemedia.10kwizard.com/contents.xml?ipage=4812791&repo=tenk','GTCB','GTC Biotherapeutics Inc')
2.783 Posts
Pagina: «« 1 ... 65 66 67 68 69 ... 140 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.062
AB InBev 2 5.514
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.721
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.738
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.753
Aedifica 3 916
Aegon 3.258 322.866
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.894
Agfa-Gevaert 14 2.050
Ahold 3.538 74.340
Air France - KLM 1.025 35.048
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.042
Alfen 16 24.902
Allfunds Group 4 1.474
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.309
AMG 971 133.611
AMS 3 73
Amsterdam Commodities 305 6.691
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.011
Apollo Alternative Assets 1 17
Apple 5 383
Arcadis 252 8.784
Arcelor Mittal 2.033 320.730
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.320
Aroundtown SA 1 219
Arrowhead Research 5 9.745
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.229
ASML 1.766 107.820
ASR Nederland 21 4.499
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.681
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.401